Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Completed 4Terminated 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 83Metastatic Castration Resistant Prostate Cancer 9Breast Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Prostate Cancer Metastatic 4Castration-resistant Prostate Cancer 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Triple Negative Breast Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Seizures 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostate Carcinoma Metastatic to the Bone 1Primary Dysautonomias 1Primary Breast Cancer ER+ve 1Pharmacokinetics of MDV3100 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-metastatic Prostate Cancer 1Metastatic Progressive Castration-resistant Prostate Cancer 1

Interventions

Prednisone 5enzalutamide 4cabazitaxel 4Docetaxel 3XRP6258 2Abiraterone Acetate 2sipuleucel-T 1rucaparib 1olaparib 1apalutamide 1Zuclomiphene 1Standard of Care 1Prednisolone 1Lenograstim 1LY3023414 1Injections 1Hematologic Tests 1Granulocyte Colony-Stimulating Factor 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Prostate Cancer Metastatic × enzalutamide × Clear all
NCT02485691 2022-05-27

CARD

Sanofi

Phase 4 Completed
255 enrolled 21 charts
Genitourinary

Prostate Cancer Metastatic

NCT02814968 2022-04-14

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

The European Uro-Oncology Group

Phase 2 Completed
66 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02815033 2022-04-14

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

The European Uro-Oncology Group

Phase 2 Completed
66 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02407054 2021-05-11

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Eli Lilly and Company

Phase 2 Completed
142 enrolled 16 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡